The Advisory Board Co. (NASDAQ:ABCO) had its price objective lifted by Barclays PLC from $44.00 to $50.00 in a research report released on Friday morning. They currently have an overweight rating on the stock.
A number of other research analysts also recently weighed in on the stock. Credit Suisse Group AG started coverage on shares of The Advisory Board in a research report on Monday, June 20th. They set an outperform rating and a $40.00 target price for the company. Zacks Investment Research raised shares of The Advisory Board from a hold rating to a buy rating and set a $40.00 target price for the company in a research report on Wednesday, July 6th. Oppenheimer Holdings Inc. reissued an outperform rating and set a $45.00 target price (up from $40.00) on shares of The Advisory Board in a research report on Friday, July 15th. Raymond James Financial Inc. downgraded shares of The Advisory Board from an outperform rating to a market perform rating in a research report on Tuesday, July 19th. Finally, FBR & Co increased their target price on shares of The Advisory Board from $35.00 to $37.00 and gave the company a mkt perform rating in a research report on Thursday, July 28th. Five equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $44.07.
Shares of The Advisory Board (NASDAQ:ABCO) traded down 1.45% on Friday, reaching $44.09. 31,389 shares of the company’s stock traded hands. The Advisory Board has a one year low of $18.87 and a one year high of $54.84. The company’s 50-day moving average price is $42.72 and its 200 day moving average price is $36.43. The firm’s market cap is $1.78 billion.
The Advisory Board (NASDAQ:ABCO) last posted its quarterly earnings data on Wednesday, July 27th. The company reported $0.47 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.34 by $0.13. The firm earned $198.40 million during the quarter, compared to analyst estimates of $196.49 million. The Advisory Board had a negative net margin of 10.21% and a positive return on equity of 11.59%. The company’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter last year, the business posted $0.40 EPS. On average, equities analysts forecast that The Advisory Board will post $1.86 EPS for the current fiscal year.
In related news, insider Cormac F. Miller sold 1,500 shares of The Advisory Board stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $43.04, for a total value of $64,560.00. Following the transaction, the insider now owns 18,987 shares in the company, valued at approximately $817,200.48. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Robert W. Musslewhite sold 5,500 shares of The Advisory Board stock in a transaction on Monday, September 12th. The stock was sold at an average price of $43.09, for a total transaction of $236,995.00. The disclosure for this sale can be found here. Insiders own 2.90% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Bank of Montreal Can acquired a new position in shares of The Advisory Board during the second quarter worth approximately $8,706,000. Fox Run Management L.L.C. acquired a new position in shares of The Advisory Board during the second quarter worth approximately $297,000. Royal Bank of Canada boosted its position in shares of The Advisory Board by 6.0% in the first quarter. Royal Bank of Canada now owns 1,252,911 shares of the company’s stock worth $40,406,000 after buying an additional 70,769 shares during the last quarter. A.R.T. Advisors LLC boosted its position in shares of The Advisory Board by 615.3% in the first quarter. A.R.T. Advisors LLC now owns 42,781 shares of the company’s stock worth $1,379,000 after buying an additional 36,800 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new position in shares of The Advisory Board during the first quarter worth approximately $6,165,000.
The Advisory Board Company Profile
The Advisory Board Company is a provider of software and solutions to the healthcare and higher education industries. The Company’s healthcare programs address a range of clinical and business issues, including physician alignment and engagement, network management and growth strategy, value-based care and population health, revenue cycle, clinical operations and supply chain.
Receive News & Ratings for The Advisory Board Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Advisory Board Co. and related companies with MarketBeat.com's FREE daily email newsletter.